-
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC
Ulas, E. B., Koomen, S. J. I., Vrijmoet, A., Houda, I., Korkmaz, H. I., Dickhoff, C., Bahce, I., Senan, S., de Gruijl, T. D., Fransen, M. F., Radonic, T., van Maldegem, F. & Schneiders, F. L., 28 Nov 2025, In: Journal for Immunotherapy of Cancer. 13, 11, e013237.Research output: Contribution to journal › Article › Academic › peer-review
-
Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)
Houda, I., Naves, D., Ulas, E. B., Lissenberg-Witte, B. I., Barlo, N. P., Kastelijn, E. A., Bouhaddou, H., Shaikh, R., Dickhoff, C., Radonic, T., Schneiders, F. L., Senan, S., Damhuis, R. A. M. & Bahce, I., 17 Nov 2025, In: Eur. J. Cancer. 230, 116042.Research output: Contribution to journal › Article › Academic › peer-review
-
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group
European Organisation for Research, Treatment of Cancer EORTC Lung Cancer Group, Nov 2025, In: Lung cancer (Amsterdam, Netherlands). 209, p. 108798Research output: Contribution to journal › Article › Academic › peer-review
- All publications
